Vivaldi Biosciences to Present Data on COVID/Influenza Nasal Spray Vaccine at

American Society for Virology Annual Meeting

FORT COLLINS, Colorado and VIENNA, Austria – July 13, 2022 – Vivaldi Biosciences, a clinical-stage biotechnology company developing nasal spray vaccines for viral respiratory diseases, today announced that the company will present data on its Delta-19 intranasal combination vaccine for Covid-19 and universal influenza at the Annual Meeting of the American Society for Virology in Madison, Wisconsin on July 17.

Delta-19 is composed of genetically modified live attenuated vaccine strains that express immunogenic antigens of SARS-CoV-2 (the virus responsible for Covid-19) and influenza viruses. The poster presentation will provide data on the development of Delta-19 and preclinical data demonstrating high levels of neutralizing antibodies for SARS-CoV-2 and influenza antigens, and protection against wild-type challenge in the ferret model.

Details of the presentation are as follows:

Presentation Title: Development of a SARS-CoV-2/Influenza Live Attenuated Intranasal Vaccine 

Authors: Alaura Hoag, Matthew Baer, Amy Aspelund, Markus Wolschek, Manfred Reiter, and Thomas Muster

Presenting Author:  Alaura Hoag, Vivaldi Biosciences

Date: July 17, 2022

Time: 8:30 pm CDT

Session / Location: P15, Exhibit Hall B

About Vivaldi Biosciences

Vivaldi Biosciences develops genetically engineered intranasal vaccines for epidemic and pandemic viral respiratory diseases. The company’s lead vaccine candidates are its DeltaFLU universal influenza vaccine in Phase 2 clinical development, and Delta-19 combination Covid-19 and universal influenza vaccine in preclinical development. Vivaldi Biosciences’ vaccine candidates are based on the company’s proprietary Delta NS1 technology platform. Delta NS1 is a vaccine vector based on genetically modified influenza virus strains. Delta NS1 vaccine strains are replication-deficient and unable to form viral progeny, which makes them safe. Vivaldi Biosciences has developed a rapid, high-yield Vero-cell based manufacturing system and produced Delta NS1 vaccines under cGMP for clinical trials. Vivaldi Biosciences is a venture-backed company with operations at the Research Innovation Center at Colorado State University, Fort Collins, Colorado, and in Vienna, Austria. NGN Capital LLC is the company’s lead investor. Learn more at www.vivaldibiosciences.com, and connect with Vivaldi Biosciences on Linkedin.

Contact

Bill Wick, CEO, Vivaldi Biosciences

Tel: +1 650-400-8915

bill.wick@vivaldibiosciences.com